trending Market Intelligence /marketintelligence/en/news-insights/trending/txmThqybKX-3iE3BSqeRlw2 content esgSubNav
In This List

US FDA expands Omeros eye drug's indication to treat children

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


US FDA expands Omeros eye drug's indication to treat children

Omeros Corp. said the U.S. Food and Drug Administration approved the expanded indication of its eye drug Omidria to treat children.

Under the label expansion, newborns and patients up to 17 years old may now receive the treatment, which is used in cataract surgery or intraocular lens replacement.

The approval was granted by the FDA under priority review. The FDA also granted the drug an additional six months of U.S. market exclusivity.